Cancer Research UK's 'Right Now' brand campaign will return in 2018 with a new focus highlighting the impact that research has on people suffering with cancer.
The agency issue, people moves, and a series of restructures top the list.
From gift bans to Google Assistant, POC to OPDP, MM&M staff members give their predictions on what to expect in healthcare marketing in 2018
How can data and analytics help drive better messaging in the pharma industry? Hans Kaspersetz, President of Arteric, chief operating officer and strategist, shares his perspective with Larry Dobrow, MM&M senior editor.
The Department of Veteran Affairs issued an RFI at the end of November for a nationwide healthcare professional recruitment campaign.
Mallinckrodt to buy Sucampo for $1.2 billion; Amazon pushes digital advertising in 2018; WHO classifies gaming disorder as mental health condition
VP of investor relations Teri Loxam will take over Ambrose's role in January.
Roche to buy Ignyta for $1.7 billion; FDA OKs Valeant eye drop for OTC sale; Kmart settles prescription drug fraud allegations
BI to pay $13.5 million for misleading marketing; ICER: CAR-T therapies more cost-effective than chemotherapy; FDA approves Roche's breast cancer combo therapy
Beiser previously held leadership roles at Edelman, Hilton, Discover, and Burson-Marsteller.
Tax bill could lead pharma to move overseas; global pharma sales increased 45% in nine years; FDA OKs first gene therapy for rare retinal disease
Brands should refrain from tweets that are over 100 characters, according to Twitter's director of brand strategy.
The Every Try Counts campaign to change how smokers see their last attempt to quit.
Pharma industry spent $57 million on lobbying in 2016; Humana, private equity firms to buy Kindred for $4 billion; price of old glaucoma drug skyrockets
CVS/Aetna deal will affect healthcare benefits; lawmakers pressure DEA to curb painkiller supply; Allergan and Richter's Vraylar sees positive results for bipolar depression
The pharma unit of Johnson & Johnson launched the Cancer.com website this month.
Pharma R&D return on investment falls to eight-year low; FDA approves Pfizer's biosimilar to J&J's Remicade; Novartis to downsize generics business
FDA approves first topical skin growth treatment; Teva to cut 14,000 jobs; Novartis Oncology CEO resigns